Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
REGN
REGN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
REGN News
Regeneron's Olatorepatide Trial Shows Significant Weight Loss Results
1d ago
Newsfilter
Regeneron's Obesity Drug Trial Shows Positive Results
1d ago
NASDAQ.COM
Regeneron and Hansoh Pharma Report Positive Phase 3 Results for Obesity Drug
1d ago
seekingalpha
Regeneron and Roche Compete in Weight Loss Drug Market
2d ago
NASDAQ.COM
Pharmaceutical Companies' Potential in Weight Loss Market
2d ago
Fool
FDA Vaccine and Biotech Chief Resigns Amid Industry Criticism
3d ago
CNBC
VHT Stock Price Analysis and ETF Dynamics
4d ago
NASDAQ.COM
Wall Street Analysts Adjust Ratings
4d ago
Benzinga
Biotech Giants Poised for Growth in 2026
5d ago
Fool
Biotech Giants Offer Growth and Safety
5d ago
NASDAQ.COM
Latest Rating Changes on Wall Street
5d ago
CNBC
REGENERON ANTICIPATES PRICING OBESITY DRUG COMPETITIVELY WITH NON-CHOLESTEROL-LOWERING THERAPIES - TD COWEN CONFERENCE
6d ago
moomoo
Chronic Kidney Disease Market Growth Drivers
6d ago
Newsfilter
EMA Recommends Dupixent Approval for Children with Chronic Urticaria
Feb 27 2026
seekingalpha
Dupixent Recommended for EU Approval to Treat Chronic Urticaria in Children
Feb 27 2026
Newsfilter
CRISPR Therapeutics Shares Surge on Strong Earnings and Pipeline Growth
Feb 26 2026
Benzinga
Show More News
